EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Additional Information

Study Phase: Phase III

Cancer Type: Renal Cell

Purpose: The primary objective of this study is to compare recurrence free survival in renal carcinoma patients randomly assigned to 54 weeks of everlimus versus 54 weeks of placebo after nephrectomy or partial nephrectomy.

  • 18 years or older
  •  Renal Cell Cancer                                                                    Clear or non-clear
  • Intermediate High Risk or Very High Risk
  • No history of distnat metastases
  • No prior anti cancer therapy

Contact: Judy Strobel RN,BSN, OCN

Clinical Research Specialist

Phone: 270-691-8094

Fax: 270-688-3673







IRB Protocol Number